FAQ

Typical timeline for a full project at Ennolys:• ~2 weeks for NDA execution.• ~2 weeks for feasibility assessment.• ~4 weeks for quotation.• 4–6 weeks to secure the first R&D slot.• Variable pilot phase (2–6 runs at 20 L scale).• ~3 months for scale-up and validation batches.Well-prepared projects can reach completion in under a year.

Key criteria include:• Equipment compatibility (fermenters, downstream processing (DSP), drying systems).• Microbiological diversity covered (bacteria, yeasts, filamentous fungi, microalgae).• Structured project roadmap with clear milestones and fixed pricing.• IP protection (NDA in place from the first exchange).• Proven track record of successful scale-up transfers from pilot to commercial batches.

Key triggers include:• A process that works in the lab but lacks the equipment to scale it up.• Downstream processing (DSP) that cannot be industrialized.• A need for prototypes for application testing or regulatory dossiers.• Insufficient CAPEX to build a production line.• Time-to-market pressure.• A requirement for quality certifications (ISO, FSSC 22000, halal, kosher) that are not available in-house.

A CRO (Contract Research Organization) operates upstream (research, screening, proof of concept) and does not engage in manufacturing. A CMO (Contract Manufacturing Organization) produces according to a provided specification sheet but does not handle development. A CDMO (Contract Development and Manufacturing Organization) both develops the process and manufactures it at industrial scale. Some players, such as Ennolys, operate as both CDMO and CMO depending on the project’s maturity.

A CDMO (Contract Development and Manufacturing Organization) oversees the development of a bioprocess and its industrial-scale manufacturing. Unlike a CMO—which executes a pre-defined, fixed process—a CDMO co-develops and optimizes the workflow, transfers it from pilot to industrial scale, and ensures commercial production. In microbial fermentation, this encompasses culture media development, parameter optimization, downstream processing (DSP), drying, and industrial validation.

The CDMO/CMO division of Ennolys is a Lesaffre business unit with over 30 years in industrial fermentation, based in Soustons, France. It offers more than 200,000 liters of fermentation capacity (vessels from 100 L to 50,000 L) and an integrated offering covering fermentation (USP), purification (DSP), drying (lyophilization, spray-drying), and quality management (FSSC 22000, ISO 9001). It supports biotech, foodtech, and industrial companies from pilot stage through commercial production, across a wide range of microorganisms (bacteria, yeasts, filamentous fungi, microalgae).

In Europe, regulation is not an end-of-project formality. It structures the process. Depending on the target application (food, nutraceutical, cosmetic, agriculture), regulatory frameworks differ — Novel Food, additives, enzymes, GMOs — with specific requirements on product identity, specifications, and process consistency. Integrating regulatory strategy from the beginning of scale-up avoids costly rework and delays at market authorization.

The choice depends on the tradeoff between control, cost, flexibility, and risk. In-house production offers maximum control but requires significant CAPEX. Toll manufacturing/CMO works when the process is already locked and the need is purely production capacity. A CDMO combines development and manufacturing: it supports the project from technology transfer through commercial production, with process development support. For biotech and foodtech companies without their own industrial infrastructure, it’s often the fastest route.

DSP can account for a significant share of production costs and overall yield loss. The higher the required purity, or the longer the purification train, the greater the risk. A purification strategy that works in the lab is not necessarily scalable, transferable to a CDMO, or economically viable at production scale. DSP must be designed as a process pillar from the outset — not added downstream.

The key challenges include oxygen and mass transfer (critical in aerobic fermentation), mixing gradients in large volumes, batch-to-batch reproducibility, industrial operational constraints (CIP/SIP, contamination prevention), and a consistently underestimated downstream processing component. The most common errors are scaling before product specs are finalized, deferring DSP design, and selecting an industrial partner without validating equipment compatibility.